VIS --- Held preparatory meeting with PMDA for the commercialization of Perfusio.

On the 18th, Veritas In Silico <130A> announced that it held a preparatory face-to-face consultation meeting with the Pharmaceuticals and Medical Devices Agency (PMDA) regarding its drug delivery system 'Perfusio' on May 14, 2026, as part of its efforts to commercialize the technology. The company is advancing drug discovery research for small-molecule and nucleic acid therapeutics targeting mRNA by leveraging its AI-driven drug discovery platform 'aibVIS,' and with respect to 'Perfusio,' it aims to achieve [specific milestone] by 2025.

Fisco Japan18:36

VIS---Due to impairment processing, an extraordinary loss has been recorded.

Veritas In Silico＜130A＞ announced on the 11th that it would incur an extraordinary loss due to impairment. After reviewing the future recoverability of tangible fixed assets acquired in the first quarter based on the 'Accounting Standard for Impairment of Fixed Assets,' the company decided to perform impairment processing in the first-quarter financial results and record an impairment loss of 135,520,000 yen as an extraordinary loss. This impairment processing will affect the first-quarter accounting period ending December 2026.

Fisco JapanMay 12 16:03

VIS has entered into a collaborative research agreement with SpiroChem to explore compounds targeting mRNA.

Veritas In Silico <130A> announced on the 11th that it has entered into a collaborative research agreement with Switzerland-based SpiroChem to explore mRNA-targeting compounds. This joint research effort will integrate SpiroChem’s world-class expertise in macrocycles, peptides, and peptoids, along with Veritas In Silico’s AI-driven mRNA-targeted drug discovery platform, aibVIS, and its cellular experimentation technology, aiming to achieve cutting-edge advancements in mRNA-targeted therapeutics at a globally leading level.

Fisco JapanMay 12 16:03

VIS---In Q1, the collaborative drug discovery research in the mRNA-targeted small molecule drug creation business progressed as planned.

Veritas In Silico＜130A＞ announced its financial results for the first quarter of the fiscal year ending December 2026 (January-March 2026) on the 11th. Business revenue decreased by 26.2% year-on-year to 17 million yen, operating loss amounted to 122 million yen (compared to a loss of 81 million yen in the same period last year), ordinary loss reached 120 million yen (compared to a loss of 79 million yen), and the quarterly net loss was 256 million yen (compared to a loss of 79 million yen). The company’s proprietary AI drug discovery platform, ibVIS（R）, which is considered its key strength...

Fisco JapanMay 12 16:03

The market appears to be firm with a prevailing buying sentiment, but upward movement may remain subdued.

[Emerging Market Stock Strategy] The emerging market is expected to remain firm today. In the U.S. stock market on August 11, the Dow Jones Industrial Average rose by 95.31 points (+0.19%) to close at 49,704.47, extending its gains. Fears over rising oil prices and interest rates due to the lack of an agreement on a peace plan between the U.S. and Iran weighed on stock prices. However, positive reactions to corporate earnings reports and buying in high-tech sectors such as semiconductors helped support the market. Today’s emerging market is likely to see buying pressure dominate. Major indices in the U.S. stock market rose yesterday.

Fisco JapanMay 12 07:20

MS&AD Insurance Group revised its operating profit forecast upward to 1.12 trillion yen from 834 billion yen for the fiscal year ending March 26.

MS&AD Insurance Group Holdings, Inc. <8725> announced a revision to its earnings forecast for the fiscal year ending March 2026, upwardly revising its operating income from 834 billion yen to 1.12 trillion yen. The improvement in performance was primarily driven by lower-than-expected insurance payouts due to natural disasters both domestically and internationally, along with disciplined underwriting practices and expanded underwriting scale in overseas operations. Additionally, gains from the sale of policy-related equity holdings exceeded expectations, leading to revisions in the projected figures for operating income and net income attributable to parent company shareholders.

Fisco JapanMay 12 04:51